Is gene therapy soon going to be used clinically in advanced cancer of the prostate?

被引：0

作者：

Gschwend, JE ^{[1
]}

Hautmann, RE ^{[1
]}

机构：

[1] Univ Ulm, Urol Klin, D-89075 Ulm, Germany

来源：

UROLOGE-AUSGABE A | 1998年 / 37卷 / 02期

关键词：

prostate cancer; gene therapy; clinical application;

D O I：

10.1007/s001200050170

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Gene transfer strategies for prostate cancer may yield promising future perspectives. In this regard, gene modified tumor vaccines, suicide gene therapy and gene replacement of nonfunctioning tumor suppressor genes are of special interest. Clinical phase I and early phase II studies with gene modified vaccines have to demonstrate the clinical implication of these new therapeutic options. Apart from this approach the development of more efficient delivery systems for in vivo gene transfer is highly desirable.

引用

页码：172 / 174

页数：3

共 18 条

[1]

Asgari K, 1997, INT J CANCER, V71, P377, DOI 10.1002/(SICI)1097-0215(19970502)71:3<377::AID-IJC13>3.3.CO

[2]

2-7

[3]

BERCHEM GJ, 1995, CANCER RES, V55, P735

[4] Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models [J].